Iovance Biotherapeutics
IOVA
139 hedge funds and large institutions have $1.05B invested in Iovance Biotherapeutics in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 28 reducing their positions, and 25 closing their positions.
171% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $567K
139% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 28
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
6% more funds holding
Funds holding: 131 → 139 (+8)
1.59% more ownership
Funds ownership: 94.66% → 96.25% (+1.6%)
3% more capital invested
Capital invested by funds: $1.02B → $1.05B (+$30.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$47.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$29.9M |
| 3 |
BlackRock
New York
|
+$20.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$20M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$15M |
| 2 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$5.11M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$4.43M |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$4.24M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.68M |
IOVA Hedge Fund Activity: Q4 2018 in Review
139 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2018, worth a combined $1.05B — up 3% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IOVA positions and 25 closed out — a net gain of 8 holders — while 67 added to existing stakes and 28 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $47.7M. The largest seller was Fidelity International, exiting entirely with an estimated $15M sold.
- 139 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2018, up from 131 in Q3 2018.
- Funds reported $1.05B of Iovance Biotherapeutics stock for Q4 2018, up 3% quarter-over-quarter.
- 33 funds opened new Iovance Biotherapeutics positions in Q4 2018 and 25 closed out, a net change of +8 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2018 was Perceptive Advisors, an estimated $47.7M added.
- The largest Iovance Biotherapeutics seller in Q4 2018 was Fidelity International, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2018.